FDA Information about Human Cell and Tissue (HCT/P) related Inspections
Earlier this year, the U.S. Food and Drug Administration published a short notice about the Inspections relating to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P's) performed in the Fiscal Years 2012 - 2016. In these years, the FDA performed between 592 and 671 inspections per year. Instead of 2012, where nearly 30% of the inspections indicated a voluntary or official action, more than 80% of the inspection results in no indicated action. The report classified the inspection in the following three groups:
- NAI = No Action Indicated, meaning no objectionable conditions or practices were found during the inspection (or the significance of the documented objectionable conditions found does not justify further action).
- VAI = Voluntary Action Indicated, meaning objectionable conditions were found and documented, but the agency is not prepared to take or recommend regulatory action.
- OAI = Official Action Indicated, meaning objectionable conditions were found and regulatory action should be recommended.
2012 | 2013 | 2014 | 2015 | 2016 | |
Number of Inspections | 592 | 671 | 652 | 598 | 636 |
Inspections Classified NAI | 432 | 520 | 524 | 501 | 541 |
Inspections Classified VAI | 151 | 145 | 130 | 97 | 97 |
Inspections Classified OAI | 15 | 13 | 8 | 8 | 5 |
Avg. hours per Inspection | 39,4 | 40,1 | 35,4 | 34,4 | 38,1 |
The number of inspections indicating an official action was decreasing in these 5 years. See also the complete data at HCT/P Inspection Information.
Related GMP News
13.11.2024Warning Letter for Manufacturer of HCT/P Products
30.10.2024Warning Letter for an American Manufacturer of Blood Products
24.10.2024Supporting biopharmaceutical Research and Development for Europe
24.10.2024Revision of USP Chapter <1047> on Gene Therapy Medicinal Products
05.09.2024Revision of USP Chapter <1033> on Validation of Biological Assays published
05.09.2024Next Generation of Genome Editing?